598 related articles for article (PubMed ID: 15771439)
1. 4-Benzyl and 4-benzoyl-3-dimethylaminopyridin-2(1H)-ones: in vitro evaluation of new C-3-amino-substituted and C-5,6-alkyl-substituted analogues against clinically important HIV mutant strains.
Benjahad A; Croisy M; Monneret C; Bisagni E; Mabire D; Coupa S; Poncelet A; Csoka I; Guillemont J; Meyer C; Andries K; Pauwels R; de Béthune MP; Himmel DM; Das K; Arnold E; Nguyen CH; Grierson DS
J Med Chem; 2005 Mar; 48(6):1948-64. PubMed ID: 15771439
[TBL] [Abstract][Full Text] [Related]
2. Structure-based design, parallel synthesis, structure-activity relationship, and molecular modeling studies of thiocarbamates, new potent non-nucleoside HIV-1 reverse transcriptase inhibitor isosteres of phenethylthiazolylthiourea derivatives.
Ranise A; Spallarossa A; Cesarini S; Bondavalli F; Schenone S; Bruno O; Menozzi G; Fossa P; Mosti L; La Colla M; Sanna G; Murreddu M; Collu G; Busonera B; Marongiu ME; Pani A; La Colla P; Loddo R
J Med Chem; 2005 Jun; 48(11):3858-73. PubMed ID: 15916438
[TBL] [Abstract][Full Text] [Related]
3. Synthesis and biological properties of novel 2-aminopyrimidin-4(3H)-ones highly potent against HIV-1 mutant strains.
Mai A; Artico M; Rotili D; Tarantino D; Clotet-Codina I; Armand-Ugón M; Ragno R; Simeoni S; Sbardella G; Nawrozkij MB; Samuele A; Maga G; Esté JA
J Med Chem; 2007 Nov; 50(22):5412-24. PubMed ID: 17910429
[TBL] [Abstract][Full Text] [Related]
4. 5-Alkyl-2-alkylamino-6-(2,6-difluorophenylalkyl)-3,4-dihydropyrimidin-4(3H)-ones, a new series of potent, broad-spectrum non-nucleoside reverse transcriptase inhibitors belonging to the DABO family.
Mai A; Artico M; Ragno R; Sbardella G; Massa S; Musiu C; Mura M; Marturana F; Cadeddu A; Maga G; La Colla P
Bioorg Med Chem; 2005 Mar; 13(6):2065-77. PubMed ID: 15727860
[TBL] [Abstract][Full Text] [Related]
5. 4-benzyl- and 4-benzoyl-3-dimethylaminopyridin-2(1H)-ones, a new family of potent anti-HIV agents: optimization and in vitro evaluation against clinically important HIV mutant strains.
Benjahad A; Courté K; Guillemont J; Mabire D; Coupa S; Poncelet A; Csoka I; Andries K; Pauwels R; de Béthune MP; Monneret C; Bisagni E; Nguyen CH; Grierson DS
J Med Chem; 2004 Oct; 47(22):5501-14. PubMed ID: 15481987
[TBL] [Abstract][Full Text] [Related]
6. Computer-aided design, synthesis, and anti-HIV-1 activity in vitro of 2-alkylamino-6-[1-(2,6-difluorophenyl)alkyl]-3,4-dihydro-5-alkylpyrimidin-4(3H)-ones as novel potent non-nucleoside reverse transcriptase inhibitors, also active against the Y181C variant.
Ragno R; Mai A; Sbardella G; Artico M; Massa S; Musiu C; Mura M; Marturana F; Cadeddu A; La Colla P
J Med Chem; 2004 Feb; 47(4):928-34. PubMed ID: 14761194
[TBL] [Abstract][Full Text] [Related]
7. 3D-QSAR models on clinically relevant K103N mutant HIV-1 reverse transcriptase obtained from two strategic considerations.
San Juan AA
Bioorg Med Chem Lett; 2008 Feb; 18(3):1181-94. PubMed ID: 18155520
[TBL] [Abstract][Full Text] [Related]
8. Novel benzophenones as non-nucleoside reverse transcriptase inhibitors of HIV-1.
Chan JH; Freeman GA; Tidwell JH; Romines KR; Schaller LT; Cowan JR; Gonzales SS; Lowell GS; Andrews CW; Reynolds DJ; St Clair M; Hazen RJ; Ferris RG; Creech KL; Roberts GB; Short SA; Weaver K; Koszalka GW; Boone LR
J Med Chem; 2004 Feb; 47(5):1175-82. PubMed ID: 14971897
[TBL] [Abstract][Full Text] [Related]
9. Indolylarylsulfones bearing natural and unnatural amino acids. Discovery of potent inhibitors of HIV-1 non-nucleoside wild type and resistant mutant strains reverse transcriptase and coxsackie B4 virus.
Piscitelli F; Coluccia A; Brancale A; La Regina G; Sansone A; Giordano C; Balzarini J; Maga G; Zanoli S; Samuele A; Cirilli R; La Torre F; Lavecchia A; Novellino E; Silvestri R
J Med Chem; 2009 Apr; 52(7):1922-34. PubMed ID: 19281225
[TBL] [Abstract][Full Text] [Related]
10. Parallel one-pot synthesis and structure-activity relationship study of symmetric formimidoester disulfides as a novel class of potent non-nucleoside HIV-1 reverse transcriptase inhibitors.
Cesarini S; Spallarossa A; Ranise A; Schenone S; Bruno O; La Colla P; Casula L; Collu G; Sanna G; Loddo R
Bioorg Med Chem; 2008 Jun; 16(12):6353-63. PubMed ID: 18502646
[TBL] [Abstract][Full Text] [Related]
11. Nonnucleoside HIV-1 reverse transcriptase inhibitors; part 3. Synthesis and antiviral activity of 5-alkyl-2-[(aryl and alkyloxyl-carbonylmethyl)thio]-6-(1-naphthylmethyl) pyrimidin-4(3H)-ones.
He Y; Chen F; Yu X; Wang Y; De Clercq E; Balzarini J; Pannecouque C
Bioorg Chem; 2004 Dec; 32(6):536-48. PubMed ID: 15530994
[TBL] [Abstract][Full Text] [Related]
12. New pyridinone derivatives as potent HIV-1 nonnucleoside reverse transcriptase inhibitors.
Le Van K; Cauvin C; de Walque S; Georges B; Boland S; Martinelli V; Demonté D; Durant F; Hevesi L; Van Lint C
J Med Chem; 2009 Jun; 52(12):3636-43. PubMed ID: 19469474
[TBL] [Abstract][Full Text] [Related]
13. 2-(2,6-Dihalophenyl)-3-(pyrimidin-2-yl)-1,3-thiazolidin-4-ones as non-nucleoside HIV-1 reverse transcriptase inhibitors.
Rao A; Balzarini J; Carbone A; Chimirri A; De Clercq E; Monforte AM; Monforte P; Pannecouque C; Zappalà M
Antiviral Res; 2004 Aug; 63(2):79-84. PubMed ID: 15302136
[TBL] [Abstract][Full Text] [Related]
14. Dihydro-alkylthio-benzyl-oxopyrimidines as inhibitors of reverse transcriptase: synthesis and rationalization of the biological data on both wild-type enzyme and relevant clinical mutants.
Mugnaini C; Alongi M; Togninelli A; Gevariya H; Brizzi A; Manetti F; Bernardini C; Angeli L; Tafi A; Bellucci L; Corelli F; Massa S; Maga G; Samuele A; Facchini M; Clotet-Codina I; Armand-Ugón M; Esté JA; Botta M
J Med Chem; 2007 Dec; 50(26):6580-95. PubMed ID: 18052319
[TBL] [Abstract][Full Text] [Related]
15. Synthesis and biological activity of naphthyl-substituted (B-ring) benzophenone derivatives as novel non-nucleoside HIV-1 reverse transcriptase inhibitors.
Ma XD; Zhang X; Dai HF; Yang SQ; Yang LM; Gu SX; Zheng YT; He QQ; Chen FE
Bioorg Med Chem; 2011 Aug; 19(15):4601-7. PubMed ID: 21719299
[TBL] [Abstract][Full Text] [Related]
16. In vitro selection of mutations in human immunodeficiency virus type 1 reverse transcriptase that confer resistance to capravirine, a novel nonnucleoside reverse transcriptase inhibitor.
Sato A; Hammond J; Alexander TN; Graham JP; Binford S; Sugita K; Sugimoto H; Fujiwara T; Patick AK
Antiviral Res; 2006 Jun; 70(2):66-74. PubMed ID: 16472877
[TBL] [Abstract][Full Text] [Related]
17. Specific targeting highly conserved residues in the HIV-1 reverse transcriptase primer grip region. Design, synthesis, and biological evaluation of novel, potent, and broad spectrum NNRTIs with antiviral activity.
Fattorusso C; Gemma S; Butini S; Huleatt P; Catalanotti B; Persico M; De Angelis M; Fiorini I; Nacci V; Ramunno A; Rodriquez M; Greco G; Novellino E; Bergamini A; Marini S; Coletta M; Maga G; Spadari S; Campiani G
J Med Chem; 2005 Nov; 48(23):7153-65. PubMed ID: 16279773
[TBL] [Abstract][Full Text] [Related]
18. Design, synthesis, and SAR of naphthyl-substituted Diarylpyrimidines as non-nucleoside inhibitors of HIV-1 reverse transcriptase.
Liang YH; Feng XQ; Zeng ZS; Chen FE; Balzarini J; Pannecouque C; De Clercq E
ChemMedChem; 2009 Sep; 4(9):1537-45. PubMed ID: 19591191
[TBL] [Abstract][Full Text] [Related]
19. Synthesis and biological evaluation of 6-substituted 5-alkyl-2-(phenylaminocarbonylmethylthio)pyrimidin-4(3H)-ones as potent HIV-1 NNRTIs.
Yu M; Li Z; Liu S; Fan E; Pannecouque C; De Clercq E; Liu X
ChemMedChem; 2011 May; 6(5):826-33. PubMed ID: 21322110
[TBL] [Abstract][Full Text] [Related]
20. Design of non-nucleoside inhibitors of HIV-1 reverse transcriptase with improved drug resistance properties. 1.
Hopkins AL; Ren J; Milton J; Hazen RJ; Chan JH; Stuart DI; Stammers DK
J Med Chem; 2004 Nov; 47(24):5912-22. PubMed ID: 15537346
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
